Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127447331 | 12744733 | 1 | I | 20160907 | 20160909 | 20160915 | 20160915 | EXP | US-AMGEN-USACT2016122620 | AMGEN | 63.00 | YR | A | M | Y | 138.00000 | KG | 20160914 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127447331 | 12744733 | 1 | PS | carfilzomib | CARFILZOMIB | 1 | Unknown | 36 MG, PER CHEMO REGIM | 202714 | 36 | MG | INTRAVENOUS INFUSION | |||||||
| 127447331 | 12744733 | 2 | SS | lenalidomide | LENALIDOMIDE | 1 | Unknown | 25 MG, PER CHEMO REGIM | 0 | 25 | MG | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127447331 | 12744733 | 1 | Plasma cell myeloma |
| 127447331 | 12744733 | 2 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127447331 | 12744733 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127447331 | 12744733 | Back pain | |
| 127447331 | 12744733 | Nephrolithiasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127447331 | 12744733 | 1 | 20160525 | 0 | ||
| 127447331 | 12744733 | 2 | 20160526 | 0 |